ANZCTR search results

To address the dearth of social media training opportunities for health promotion and public health professionals, we intend to evaluate the impact of a MOOC that aims to improve their knowledge and understanding of how to effectively frame health promotion messages and increase their perceived confidence in using social media for health promotion communication and advocacy. A mixed-methods approach, incorporating quantitative pre-and post-surveys and qualitative structured individual interviews, will be used to gain a deeper understanding of both the immediate and long-term effects of the MOOC on various outcomes.

This study aims to assess whether vaginal swabs self-collected using the Abbott simpli-COLLECT kit and self-collected urine samples using the Novosanis Colli-pee device have similar clinical performance detecting HPV associated with cervical disease, compared with the reference practitioner-collected cervical samples. Who is it for? You may be eligible to participate in this study if you are a female aged 25 or above, and has colposcopy referral based on abnormal result of a test within the cervical screening program.. Study details All participants in this study will attend a single clinical appointment, during which time they will be asked to take two self-collected samples, one using a swab to collect a vaginal sample, and the other being a urine sample, and compare them against the standard of care clinician- collected specimen from the cervix for the detection of Human Papillomavirus (HPV) using any colposcopy biopsy findings as the reference for sensitivity and specificity for cervical disease. It is hoped that the results from this study will identify a new option for people wanting to participate in cervical screening.

This trial will be assessing Immune-12 as an adjunct treatment to standard care for GBM. Who is it for? You may be eligible to join this study if you are aged 18 years old or above and have a diagnosis of Glioblastoma multiforme (GBM). Have had magnetic resonance imaging (MRI) of their tumour/s within the 4 months prior to Screening Visit. Have a Karnofsky score of equal to or greater than 50 and ability to swallow liquids (Naso-gastric feeding tubes are allowed). Study details All participants who choose to enrol in this study will be asked to take 2 sachets of Immune-12 twice a day for 24 weeks. Participants will be regularly assessed throughout the study for tumour measurement, potential biomarkers, blood markers, quality of life and functionality, steroid usage, inflammation and oedema, and adverse events. It is hoped that the IMMUNE-12 will help reduce disease progression, tumour growth and potential reoccurrence.

We hypothesise that when Aboriginal Health Workers (AHWs) and practitioners (AHPs) are trained to offer point of care ultrasound scan to detect fetal heartbeat, it will encourage Aboriginal women to engage in the antenatal care process earlier and thereby improve pregnancy outcomes. Therefore, the overarching goal of the proposed pilot study is to improve prenatal care in Aboriginal Torres Strait Islander women in rural Australia through upskilling AHWs and AHPs in one Point of care ultrasound antenatal module. To ensure that the training program meets the needs of the community, a co-design process will be used for development of the educational program and training materials as well as recruitment of participants.

We aim to determine if a 6-session course of reconsolidation blockade (i.e., oral propranolol treatment combined with script-driven trauma recall) is efficacious in reducing PTSD symptom frequency and severity in adults 18years +. We will also examine the psychosocial, neurocognitive, neurobiological, neuroimaging and physiological effects of reconsolidation blockade treatment in adult participants with PTSD. Our research questions include: 1. Primary question: Will a 6-session reconsolidation blockade treatment be efficacious in reducing core PTSD symptoms frequency and severity? 2. Secondary question: Are there psycho-social, cognitive, and biological markers (genetic, circulating, and neural) that can predict treatment response to reconsolidation blockade treatment?

This is a study to determine if the FUNCAP 27 can be used as an instantaneous measure of perceived functional capacity in those with ME/CFS and Long Covid when at baseline and in a state of PEM(Post Exertional Malaise). We are doing this to establish a measure that can detect short term fluctuations in health that will be used in later interventional clinical trials. We aim to recruit 1000 participants for 2 questionnaires and 1 enrolment survey taking 6-20 minutes at enrolment (including reading the consent forms), 15-35 minutes when well and 10 -20 minutes in PEM. The questionnaire can be completed with the aid of a carer and paused for completion at a later time.

In the intensive care unit (ICU), non-invasive ventilation (NIV) is a treatment option for patients with respiratory failure. NIV involves the delivery of oxygenated air from a ventilator to the patient via a mask. The mask is secured to the patient’s head using straps that sit around the head to hold the mask over the nose and mouth. The purpose of NIV is to reduce the likelihood of invasive mechanical ventilation that requires the insertion of an artificial airway or breathing tube. Traditionally NIV masks cover the entire nose and mouth, resting on the nasal bridge. This can in rare instances lead to the development of pressure injuries on the bridge of the nose and as such facial disfiguration. At Sunshine hospital the Nivairo® mask is routinely used for NIV. This mask sits across the nasal bridge. In this study we would like to determine if the Visairo® mask that does not have a nasal bridge is equivalent to the Nivairo® mask for the delivery of NIV.

This study aims to assess the safety and feasibility of using tranexamic acid (TXA) in patients with cerebral amyloid angiopathy (CAA) and symptomatic brain bleeding to determine if TXA can reduce risk of recurrent intracranial haemorrhage without harmful side effects. We hypothesise TXA to be a safe and well tolerated treatment option for patients with CAA in reducing their risk of recurrent brain bleeding. Participants will be recruited from Alfred Health and Royal Melbourne Hospital, diagnosed with probable CAA, who have had previous brain bleeding within the last 6 months. They will be randomly assigned to take either 1 gram of TXA orally three times per day or an identical placebo for 6 months. All participants will have MRI scans with contrast and blood tests at the start and end of the study to measure biomarkers. Researchers will track participants' compliance with the treatment and any adverse events over the 6-month period. Primary outcomes will include feasibility measures (participation and adherence rates) and safety (monitoring for serious adverse events like clotting conditions, heart attacks, strokes, or death). Secondary outcomes will track the recurrence of various brain haemorrhages, progression of white matter changes, changes in cognitive function, and brain volume loss, as well as the development of new strokes.

This study is a data collection study of the EMVision emu™ brain scanner for patients not suffering from or suspected of suffering from an acute stroke for software algorithm development. This study collects EMVision brain scans and MRI scans from patients receiving a head MRI as part of their routine care. Scans are anonymised and enter the EMVision database for training and developing software algorithms. This study hypothesises that an expanded non-stroke dataset can improve the diagnostic performance of the emu™ brain scanner.

The aim of this study is to test whether MDMA-assisted psychotherapy reduces social anxiety in young autistic people, compared with medication-assisted psychotherapy using: • Dexamfetamine • Lorazepam • Diphenhydramine hydrochloride, and • placebo. We hypothesise that MDMA-assisted psychotherapy will reduce social anxiety more than medication psychotherapy with placebo or the active control medications. Young people with autism, aged 16 to 25 years and experiencing social anxiety can take part in this research. The study will involve assessment for autism if participants have not been diagnosed in the past year. Participation will involve taking part in a medication-assisted psychotherapy program over a period of 12 weeks in addition to participating in a number of research assessments for approximately one year.